GlassScriptPhysician profile
Helen Feng
NPI 1629174149
$33,556.60
in general payments reported to CMS, 2019-2025
40 companies · $5,136 in 2025
The $5,136 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,167 · 2020: $2,785 · 2021: $3,447 · 2022: $3,903 · 2023: $5,069 · 2024: $6,048 · 2025: $5,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,977.14 |
| Education | $276.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,214.37 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $5,041.91 | 2019-2025 | |
| Ucb, INC. | $2,823.74 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $2,490.61 | 2019-2025 | Tremfya, Stelara, Simponi |
| Glaxosmithkline, LLC. | $1,805.76 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,704.34 | 2019-2025 | |
| Horizon Therapeutics Plc | $1,573.10 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $1,496.05 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $1,495.71 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,415.79 | 2019-2025 | |
| Radius Health, INC. | $1,099.54 | 2019-2025 | Tymlos |
| Amarin Pharma, INC. | $684.41 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $570.00 | 2019-2024 | Cyltezo |
| Genzyme Corporation | $540.09 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $479.93 | 2021-2025 | Lupkynis |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Feng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.